{
  "id": 462987,
  "title": "Silence spells out Phase 2 success for gene-silencing drug in rare blood cancer",
  "url": "https://urgent.news/2026/08/10/silence-spells-out-phase-2-success-for-gene-silencing-drug-in-rare",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-10T11:31:25.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/silence-spells-out-phase-2-success-for-gene-silencing-drug-in-rare-blood-cancer/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Silence Therapeutics is set to advance its siRNA drug for the rare blood disorder polycythemia vera (PV) into Phase 3 following a successful mid-stage trial. Silence said its drug divesiran met the primary endpoint in ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "STAT News",
        "title": "STAT+: Silence Therapeutics aims at Takeda with new data in rare blood cancer",
        "url": "https://urgent.news/2026/08/10/stat-silence-therapeutics-aims-at-takeda-with-new-data-in-rare-blood",
        "published": "2026-08-10T11:31:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}